[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chronic-low-back-pain\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chronic-low-back-pain":655},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,89,0,25,[9,44,76,103,114,145,169,194,226,251,278,309,331,352,379,401,424,446,478,501,528,555,579,608,629],{"id":10,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100053806",false,"NCT06827262","Intracept Minimally-invasive PROcedure for VErtebrogenic Back Pain","IMPROVE","Inclusion Criteria:\n\n* Study candidate is scheduled to be treated with a commercially approved Intracept™ Intraosseous Nerve Ablation System per local Instructions for Use (IFU).\n* Signed a valid, IRB\u002FEC-approved informed consent form.\n\nExclusion Criteria:\n\n* Meets any contraindications per locally applicable Instructions for Use (IFU).","ALL","18 Years",{"count":19,"type":20},1500,"ESTIMATED","60 Months","OBSERVATIONAL","Compile real-world outcomes of commercially approved Intracept™ Intraosseous Nerve Ablation Systems in the treatment of patients diagnosed with vertebrogenic pain.",[25,26],"Chronic Low-back Pain","Vertebrogenic Pain Syndrome",[28,29,30],"Intraosseous basivertebral nerve ablation","Axial low back pain","Low Back Pain","RECRUITING","2026-07-10",{"date":34,"type":35},"2026-07-13","ACTUAL",{"date":37,"type":35},"2025-03-26",{"date":39,"type":20},"2034-07",{"name":41,"class":42},"Boston Scientific Corporation","INDUSTRY",18,{"id":45,"slug":4,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":57,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":75},"100524243","NCT06106191","Integrative Mindfulness-Based Predictive Approach for Chronic Low Back Pain Treatment","IMPACT","Inclusion Criteria:\n\n* Chronic low back pain, which is pain that persists for at least 3-months and has resulted in pain on at least half the days in the past 6 months\n* Willing and able to provide online or telephone informed consent\n* Speak English as the intervention manual is currently written in English\n\nExclusion Criteria:\n\n* Red flags- recent (past month) worsening of pain, unexplained fever, unexplained weight loss\n* Pregnancy\n* Metastatic cancer\n* Not a patient at a participating clinic or persons not planning to continue as a patient at a participating clinic for 6 or more months",{"count":51,"type":20},350,"INTERVENTIONAL",[54],"NA","This study will identify unique signatures that people have which can cause pain by evaluating biological, psychological, and social markers using artificial intelligence. These markers can be used to accurately predict the response of diverse individuals with chronic low back pain (cLBP) to Mindfulness-Based Stress Reduction. This will help enhance clinician decision-making and the targeted treatment of chronic pain.\n\nThe overall objective is to use a unique machine learning (ML) approach to determine the biomarker signature of persons undergoing mindfulness based stress reduction (MBSR) treatment for their chronic low back pain (cLBP). This signature will facilitate clinical prediction and monitoring of patient response to MBSR treatment.\n\nThe design of the study is a single-arm clinical trial of the evidence-based MBSR program for patients with cLBP.",[25],[58,59,60,61,62,63,64],"Mindfulness based stress reduction (MBSR)","Machine learning (ML)","Biopsychosocial data","PEG (Pain, Enjoyment, General activity)","Pain interference","Pain intensity","Depression","2026-06-29",{"date":67,"type":35},"2026-06-30",{"date":69,"type":35},"2024-07-25",{"date":71,"type":20},"2029-12",{"name":73,"class":74},"Boston Medical Center","OTHER",1,{"id":77,"slug":4,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":16,"minAge":83,"maxAge":84,"enrollmentInfo":85,"targetDuration":4,"studyType":52,"phases":87,"briefSummary":88,"conditions":89,"keywords":91,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":75},"100645347","NCT07681336","Auricular Vagus Nerve Stimulation in Patients With High Impact Chronic Low Back Pain","Auricular Vagus Nerve Stimulation in Patients With High Impact Chronic Low Back Pain - a Prospective, Interventional, Open, Randomized, Controlled, Single-center Trial","VIVO","Inclusion Criteria:\n\n* Male or female patients aged ≥ 30 and ≤ 60 years;\n* High impact lumbar or lumbosacral myofascial\u002Fmusculoskeletal chronic (\\> 6 months) low back pain that is moderate to severe (defined as average pain over the last 4 weeks ≥ 5 on the NRS at baseline);\n* Normal function of lumbosacral nerves based on clinical assessment;\n* Unresponsive\u002Fintolerance (meaning insufficient pain reduction or intolerance) to oral pharmacotherapy (World Health Organization (WHO) grade II);\n* ODI 21-80 at baseline;\n* Patient understands the therapy and procedures, agrees to its provisions, and gives written informed consent prior to any procedures\n\nExclusion Criteria:\n\n* Organic low back pain (trauma, fracture, tumor, infection, documented severe degenerative spine, documented high-grade spinal stenosis, rheumatologic conditions);\n* Indication for back surgery;\n* Radicular pain;\n* New analgesics 2 weeks before baseline (paracetamol, NSAIDs, etc.);\n* Opioid analgesic therapy;\n* Underwent other physical therapy modalities, including TENS, ultrasound, infiltration, RF-treatment, 2 weeks before screening;\n* History of Vagus Nerve Stimulation or ear stimulation;\n* History of vasovagal syncope;\n* BMI \\> 35 kg\u002Fm² (Obesity Class 2 or higher);\n* Hemophilia;\n* Documented autonomic disorders;\n* Advanced stage or poorly controlled diabetes mellitus type I or II\n* Poorly controlled high blood pressure at baseline (systolic blood pressure (SBP) \\> 160 mmHg);\n* Major psychiatric comorbidity (HADS ≥ 10 on each subscale at baseline);\n* Other serious clinically relevant co-morbidity, florid malignant conditions or neurological diseases;\n* History of arrhythmia, bradycardia, other rhythm disorders or any other clinically significant cardiac anomalies;\n* Use of prescription blood thinners, e.g., oral anticoagulants (marevan, sintrom, marcoumar), noval oral anticoagulants (pradaxa, xarelto, eliquis, lixiana), anti-platelet medication (asaflow);\n* Infection, eczema, or psoriasis at application site (ear and neck);\n* Numbed and desensitized skin at the application site (ear and neck);\n* Serious drug-related behavioral issues (e.g., alcohol dependency, illegal substance abuse) in the last 6 months;\n* Pregnant, parturient or breast-feeding women;\n* Active implantable device (e.g. cardiac pacemaker, defibrillator, cochlear implant, neurostimulator like Spinal Cord Stimulation or Peripheral Nerve Stimulation) ;\n* Currently participating in another interventional clinical trial or participated over the last 3 months;\n* Patients who are unable to sufficiently speak and write in the Dutch language;\n* Mental and physical impairments that represent a source of risk for handling the device;\n* Patients under legal protection (curatorship, guardianship);\n* Patients subject to a legal protection measure;\n* An adult who is incapable or unable to give consent.","30 Years","60 Years",{"count":86,"type":20},44,[54],"The goal of this clinical trial is to evaluate whether auricular vagus nerve stimulation using the VIVO® device can improve function and reduce pain in adults with high-impact chronic low back pain when added to standard medical care. It will also assess the safety and usability of this therapy.\n\nThe study includes adult patients aged 30 to 55 years who have had moderate to severe chronic low back pain for more than 6 months and who did not experience sufficient relief with standard pain treatments.\n\nThe main questions this study aims to answer are:\n\n* Does adding the VIVO® device to standard care help people function better in daily life?\n* Does the VIVO® device help lower pain and improve wellbeing, sleep, and quality of life?\n\nResearchers will compare standard care plus VIVO® to standard care alone to see if the device improves outcomes.\n\nStandard care may include medication, physiotherapy, or other usual treatments.\n\nThe main outcome is the change in disability (measured using the Oswestry Disability Index) after 6 weeks of treatment.\n\nParticipants will:\n\n* Attend a baseline visit where medical history, physical examination, and questionnaires about pain, function, mood, sleep, and quality of life are collected;\n* Be randomly assigned to one of the two treatment groups;\n* Attend weekly visits for 6 weeks during the treatment phase;\n* Keep a diary of their pain levels and any treatments or medications used;\n* Complete questionnaires about pain, function, sleep, and wellbeing during the study.\n\nParticipants in the intervention group will:\n\nReceive a VIVO® wearable device applied to the ear, which delivers electrical stimulation to the vagus nerve; Use the device continuously over 6 weeks, with weekly replacement and adjustment of stimulation settings; Be able to adjust the stimulation intensity themselves using a handheld device.\n\nAfter the treatment period, all participants will be followed for 12 months, with additional visits or contacts to assess long-term effects, safety, and sustainability of the treatment.",[90],"Chronic Low Back Pain",[92,93],"auricular vagus nerve stimulation","VIVO device","2026-06-26",{"date":96,"type":35},"2026-07-02",{"date":98,"type":35},"2026-03-04",{"date":100,"type":20},"2028-09",{"name":102,"class":74},"Algemeen Ziekenhuis Maria Middelares",{"id":104,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":105,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":106,"keywords":107,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":112,"leadSponsor":113,"locationsCount":43},"100579666",{"count":19,"type":20},[25,26],[28,29,30],"2026-06-23",{"date":110,"type":35},"2026-06-24",{"date":37,"type":35},{"date":39,"type":20},{"name":41,"class":42},{"id":115,"slug":4,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":4,"eligibilityCriteria":119,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":120,"enrollmentInfo":121,"targetDuration":4,"studyType":52,"phases":123,"briefSummary":124,"conditions":125,"keywords":132,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":137,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":144},"100465768","NCT05345015","High Frequency RF Current Effects on Muscle Pain and Function","Acute and Chronic Effects of High Frequency RF Electrical Current on Pain and Muscle Function in Individuals With Musculoskeletal Pain","Individuals with Muscle Injury\n\nInclusion Criteria:\n\n* Age over 18 years.\n* Athletes: amateur soccer players or sprinters with regular, systematic training.\n* Suspected Grade I or II hamstring strain.\n* Cessation of training due to injury.\n* No surgical intervention in the previous year (for initial assessment as potential participants).\n\nExclusion Criteria:\n\n* History of injury to the same muscle (ipsilateral side) within the last 6 months.\n* Other injury to the posterior aspect of the thigh.\n* Other injuries or chronic pain in the trunk or lower limbs.\n* Use of non-steroidal anti-inflammatory drugs (NSAIDs) in the 3 months prior to the injury.\n\nIndividuals with Acute Low Back Pain\n\nInclusion Criteria:\n\n* Age over 18 years.\n* Pain located between the lower ribs and the gluteal folds (top of the buttocks).\n* Pain occurred on fewer than half of the days over the preceding six months.\n* Pain intensity $\\\\ge$ 6\u002F10 on the Visual Analogue Scale (VAS).\n* Pain related to one or more of the following:\n\n  * Lumbar facet joints\n  * Sacroiliac joints\n  * Lumbar intervertebral discs\n  * Muscles, tendons, or ligaments of the lumbar and sacral region\n  * Other bony structures of the lumbar spine\n* Discontinuation of non-steroidal anti-inflammatory drugs (NSAIDs) or analgesics:\n\n  * 1 day prior to measurement\n  * 48 hours after measurement\n\nExclusion Criteria:\n\n* Radiographic evidence of inflammatory disease affecting the spine.\n* Spinal fracture.\n* Significant genetic structural abnormality of the spine.\n* Pregnancy.\n* Psychiatric disorders.\n* Receipt of systemic medication or treatment in the last 3 months.\n* Presence of neurological deficits (sensory, motor, or reflexes).\n* Receipt of TENS or TECAR therapy within the last year.\n\nIndividuals with Chronic Low Back Pain\n\nInclusion Criteria:\n\n* Episodes of low back pain (between the lower rib margin and the gluteal fold) for at least half of the days during the last 6 months.\n* Pain intensity $\\\\ge$ 20% on the Visual Analogue Scale (VAS).\n\nExclusion Criteria:\n\n* Spinal stenosis.\n* Radiographic evidence of inflammatory disease affecting the spine.\n* Vertebral fracture.\n* Presence of spondylolisthesis or spondylolytic lesion (spondylolysis).\n* Significant genetic structural abnormality of the spine.\n* Daily, severe low back pain.\n* Pregnancy.\n* Use of medications that might influence heart rate or blood pressure.\n* Psychiatric disorders.","65 Years",{"count":122,"type":20},200,[54],"The purpose of this study is to examine the acute and chronic effects of high frequency electrical current transfer (frequently called \"TECAR\") on pain and functional movement in individuals with a musculoskeletal injury or pain. The participants will be assigned into an experimental or a control group and outcome measures will be measured prior to, after, 24 and 48 hours following a single intervention session (Acute effects) as well as 3 and 6 months after the intervention (chronic effects).",[126,25,127,128,129,130,131],"Transcutaneous Electric Nerve Stimulation","Hamstring Injury","Muscle; Injury, Quadriceps (Thigh)","Physical Therapy","Calf Muscle Pulled","Acute Low Back Pain",[133,134,135,136],"Sport injuries","TECAR therapy","Low back pain","Muscle injury",{"date":94,"type":35},{"date":139,"type":35},"2022-09-01",{"date":141,"type":20},"2029-12-31",{"name":143,"class":74},"Aristotle University Of Thessaloniki",2,{"id":146,"slug":4,"hasResults":11,"nctId":147,"briefTitle":148,"officialTitle":149,"acronym":150,"eligibilityCriteria":151,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":152,"targetDuration":4,"studyType":52,"phases":154,"briefSummary":156,"conditions":157,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":168},"100515037","NCT05986292","A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic Pain","A Master Protocol for Randomized, Placebo-Controlled, Phase 2 Clinical Trials of Multiple Interventions for the Treatment of Chronic Pain","CPMP","Inclusion Criteria:\n\n* have a visual analog scale (VAS) pain value \\>40 and \\\u003C95 at screening and prerandomization screening.\n* have a history of daily pain for at least 12 weeks based on participant report or medical history\n* have a value of ≤30 on the pain catastrophizing scale\n* have a body mass index \\\u003C40 kilogram\u002Fsquare meter (kg\u002Fm²) (inclusive)\n* are willing to maintain a consistent regimen of any ongoing nonpharmacologic pain-relieving therapies (for example, physical therapy) and will not start any new nonpharmacologic pain-relieving therapies during study participation.\n* are willing to discontinue all medications taken for chronic pain conditions, except rescue medication for the duration of the study\n\nExclusion Criteria:\n\n* have second- or third-degree atrioventricular (AV) heart block or AV dissociation or history of ventricular tachycardia\n* have had a procedure within the past 6 months intended to produce permanent sensory loss in the target area of interest (for example, ablation techniques)\n* have surgery planned during the study for any reason, related or not to the disease state under evaluation.\n* have, in the judgment of the investigator, an acute, serious, or unstable medical condition or a history or presence of any other medical illness that would preclude study participation.\n* have had cancer within 2 years of baseline, except for cutaneous basal cell or squamous cell carcinoma resolved by excision.\n* have fibromyalgia\n* have substance use disorder as defined by the Diagnostic and Statistical Manual of Mental Disorders (5th edition; DSM-5; American Psychiatric Association)\n* have any clinically important abnormality at screening, as determined by investigator, in physical or neurological examination, vital signs, electrocardiogram (ECG), or clinical laboratory test results that could be detrimental to the participant or could compromise the study.\n* have a positive human immunodeficiency virus (HIV) test result at screening\n* have a history of alcohol, illicit drug, analgesic or narcotic use disorder within 2 years prior to screening.",{"count":153,"type":20},10000,[155],"PHASE2","The purpose of the chronic pain master protocol is to compare independent pain interventions and establish an overarching structure for the disease-state addenda (DSA) and intervention-specific appendices (ISAs). The ISAs may start independently of other ISAs as interventions become available for clinical testing.",[158,159,25],"Osteoarthritis, Knee","Diabetic Neuropathic Pain","2026-06-19",{"date":108,"type":35},{"date":163,"type":35},"2020-01-30",{"date":165,"type":20},"2027-04",{"name":167,"class":42},"Eli Lilly and Company",64,{"id":170,"slug":4,"hasResults":11,"nctId":171,"briefTitle":172,"officialTitle":172,"acronym":173,"eligibilityCriteria":174,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":175,"enrollmentInfo":176,"targetDuration":4,"studyType":52,"phases":178,"briefSummary":179,"conditions":180,"keywords":181,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":192,"locationsCount":75},"100478518","NCT05511012","Does the Therapist's Assessment of Movement Control in Low Back Pain Patients Correspond to an Objective Kinematic Modification","LOBACOM","Inclusion Criteria:\n\n* Aged more than 18 years\n* Common low back pain with medical prescription for rehabilitation\n* Signed consent\n* Be affiliated to a social security scheme\n* Be able to perform the lumbar motion control failure tests\n\nExclusion Criteria:\n\n* Body Mass Index greater than 30 (obesity)\n* Person who does not understand French\n* Pregnant woman\n* Refusal to participate\n* Volunteer under guardianship or curatorship","99 Years",{"count":177,"type":20},50,[54],"* Exercise-based treatment is part of the recommendations for good practice in the treatment of low back pain (acute, sub-acute and chronic).\n* The low back pain population is heterogeneous. This heterogeneity would cause the positive effects of a treatment to be canceled out by the negative effects of another part of the population.\n* This polymorphism has led several authors to classify low back pain into subgroups. These subgroups constitute more homogeneous clinical pictures and would facilitate the adaptation of treatments.\n* The recommendations of the American Physical Therapy Association suggest 5 subgroups of low back pain. One of them is \"low back pain with movement coordination defect\". In this subgroup, Luomajoki studied the reliability of different functional tests used in clinical practice. 6 out of 10 motion control fault tests show good reliability.\n* The quantified analysis of the movement of low back pain patients would make it possible to determine the sensitivity of detecting an anomaly in the 6 lumbar movement control tests.",[25],[135,182,183,184],"Movement control","Kinematic analysis","Clinical assessment","2026-06-09",{"date":187,"type":35},"2026-06-11",{"date":189,"type":35},"2022-12-15",{"date":191,"type":20},"2026-12-15",{"name":193,"class":74},"University Hospital, Brest",{"id":195,"slug":4,"hasResults":11,"nctId":196,"briefTitle":197,"officialTitle":197,"acronym":4,"eligibilityCriteria":198,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":199,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":201,"conditions":202,"keywords":4,"overallStatus":216,"whyStopped":4,"lastUpdateSubmitDate":217,"lastUpdatePostDateStruct":218,"startDateStruct":220,"completionDateStruct":222,"leadSponsor":224,"locationsCount":4},"100643683","NCT07639060","Prospective Case Series Evaluating 6-Month and 12-Month Outcomes After Cryoneurolysis for Chronic Pain","Inclusion Criteria:\n\n* Diagnosis of chronic pain (generally pain duration of at least 3-6 months) localized to an anatomical region appropriate for cryoneurolysis as determined by the treating physician.\n* Planned cryoneurolysis procedure as part of standard clinical care.\n* Ability to provide written informed consent.\n* Ability and willingness to complete baseline and follow-up questionnaires.\n\nExclusion Criteria:\n\n* Cryoneurolysis performed as part of a separate investigational trial in which data sharing is not permitted.\n* Active infection or other clinical contraindication to the procedure as determined by the treating clinician.\n* Life expectancy of less than 12 months in the judgment of the treating clinician.\n* Any condition that, in the investigator's opinion, would interfere with study participation or completion of follow-up, such as severe psychiatric instability or active substance use that precludes reliable follow-up",{"count":200,"type":20},80,"To prospectively describe patient-centered and health utilization outcomes through 12 months after cryoneurolysis performed as routine clinical care for chronic pain at Yale.",[203,204,205,206,207,208,209,90,210,211,212,213,214,215],"Chronic Pain","PERIPHERAL NEUROPATHY","Occipital Neuralgia","Chronic Hip Pain","Hip Osteoarthritis","Knee Osteoarthritis","Spasticity","Lumbar Spondylosis","Cervical Spondylosis","Shoulder Arthritis","Causalgia","Chronic Pain Syndrome","Chronic Neck Pain","NOT_YET_RECRUITING","2026-06-05",{"date":219,"type":35},"2026-06-10",{"date":221,"type":20},"2026-06",{"date":223,"type":20},"2028-07",{"name":225,"class":74},"Yale University",{"id":227,"slug":4,"hasResults":11,"nctId":228,"briefTitle":229,"officialTitle":230,"acronym":231,"eligibilityCriteria":232,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":233,"targetDuration":4,"studyType":52,"phases":235,"briefSummary":236,"conditions":237,"keywords":241,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":243,"lastUpdatePostDateStruct":244,"startDateStruct":245,"completionDateStruct":247,"leadSponsor":249,"locationsCount":250},"100607611","NCT07190807","Managing Pain Using Optimized Sequences by Adjusting Parameters With Independent Current Control","Managing Pain Using Optimized Sequences by Adjusting Parameters With Independent Current Control (MOSAIC Study)","MOSAIC","Key Inclusion Criteria:\n\n* Persistent spinal pain syndrome (PSPS) Type I (or non-surgical refractory back pain), or PSPS Type II (Failed Back Surgery Syndrome, FBSS) diagnosis.\n* Diagnosed with chronic pain of the trunk and\u002For limbs for at least 6 months.\n* 18 years of age or older when written informed consent is obtained\n* Able to independently read and complete all questionnaires and assessments provided in English.\n* Signed a valid, IRB or EC approved informed consent form (ICF) provided in English.\n\nKey Exclusion Criteria:\n\n* Any pain-related diagnosis, medical or psychological condition that, in the Investigator's judgment might confound reporting of study outcomes (e.g., vascular or neurogenic claudication, osteoarthritis, plantar fasciitis, pelvic pain, anginal pain, chronic migraine, acute herniated disc, malignancy, untreated major depression, injury claim).\n* Significant cognitive impairment at Screening and Baseline visit that, in the opinion of the Investigator, would reasonably be expected to impair the study candidate's ability to participate in the study\n* A female who is pregnant, lactating, or is of childbearing potential and planning to get pregnant during the study or not using adequate contraception.\n* Participating (or intends to participate) in another drug or device clinical trial that may influence the data that will be collected for this study.",{"count":234,"type":20},70,[54],"Study to evaluate the effectiveness of time variant pulse (TVP)-SCS in patients with chronic pain using commercially approved Boston Scientific SCS Systems per local Instructions for use (IFU).\n\nIn addition, to compile real-world clinical outcomes in subjects with chronic, intractable low back and\u002For leg pain.",[203,238,30,25,239,240],"Intractable Pain","Chronic Leg Pain","Leg Pain",[242],"Spinal Cord Stimulation","2026-06-04",{"date":217,"type":35},{"date":246,"type":35},"2025-11-07",{"date":248,"type":20},"2029-05",{"name":41,"class":42},7,{"id":252,"slug":4,"hasResults":11,"nctId":253,"briefTitle":254,"officialTitle":255,"acronym":256,"eligibilityCriteria":257,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":258,"targetDuration":4,"studyType":52,"phases":260,"briefSummary":261,"conditions":262,"keywords":263,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":243,"lastUpdatePostDateStruct":270,"startDateStruct":272,"completionDateStruct":274,"leadSponsor":276,"locationsCount":144},"100552348","NCT06471920","Improving Health for Patients With Chronic Low Back Pain in Rural Communities Through Telerehabilitation","ARBOR Telehealth: Improving Health for Patients With Chronic Low Back Pain in Rural Communities Through Improved Access to Telerehabilitation","ARBOR-Th","Inclusion Criteria:\n\n* Primary care visit in the past 90 days with an LBP-related International Classification of Diseases (ICD-10) diagnosis.\n* Age 18 years or older.\n* At least moderate levels of pain and disability requiring Oswestry score ≥24% and average pain rating ≥ 4\u002F10 points.\n* Meets NIH Task Force definition of chronic LBP based on two questions: 1) How long has LBP has been an ongoing problem? and 2) How often has LBP been an ongoing problem over the past 6 months? A response of greater than 3 months to question 1, and \"at least half the days in the past 6 months\" to question 2 is required to satisfy the NIH definition of chronic LBP.\n* Can speak and understand English.\n* Access to video-enabled device and Internet.\n\nExclusion Criteria:\n\n* Recent history (last 6 months) of lumbar spine surgery.\n* Possible non-musculoskeletal cause for low back pain symptoms (e.g., pregnancy).\n* Evidence of serious pathology as a cause of LBP including neoplasm, inflammatory disease (e.g., ankylosing spondylitis), vertebral osteomyelitis, etc.\n* Neurological disorder resulting in severe movement disorder, or schizophrenia or other psychotic disorder.\n* Knowingly pregnant.",{"count":259,"type":20},434,[54],"Physical therapy is the first line of treatment for patients with low back pain (LBP) and has been shown to be a cost-effective method for improving pain and disability in patients with chronic LBP; however, despite this effectiveness, only 7-13% of patients go on to receive physical therapy services with patients in rural communities being especially limited to do lack of provider availability, transportation, and missed work time leading to greater rates of LBP-related disability and opioid consumption. With the rapid emergence of digital treatment approaches to physical therapy (i.e., telerehabilitation), access could be improved by reducing or eliminating many barriers that patients report; however, it is unclear how to appropriately incorporate digital treatment approaches into existing health care models. The investigators propose a prospective randomized clinical trial conducted at a health system serving rural communities to determine the effectiveness of innovative risk-informed telerehabilitation versus standard educational control for patients with chronic LBP that will match individual patients with specific physical therapy delivery (physical therapy telehealth visits or psychologically informed physical therapy telehealth visits) based on the patient's psychosocial risk of poor outcomes.",[25],[264,265,266,267,268,269],"chronic low back pain","physical therapy","Telehealth","telerehabilitation","rural","opioid",{"date":271,"type":35},"2026-06-08",{"date":273,"type":35},"2025-01-27",{"date":275,"type":20},"2028-08-31",{"name":277,"class":74},"Johns Hopkins University",{"id":279,"slug":4,"hasResults":11,"nctId":280,"briefTitle":281,"officialTitle":282,"acronym":283,"eligibilityCriteria":284,"healthyVolunteers":11,"sex":16,"minAge":285,"maxAge":4,"enrollmentInfo":286,"targetDuration":4,"studyType":52,"phases":288,"briefSummary":290,"conditions":291,"keywords":293,"overallStatus":216,"whyStopped":4,"lastUpdateSubmitDate":300,"lastUpdatePostDateStruct":301,"startDateStruct":302,"completionDateStruct":304,"leadSponsor":306,"locationsCount":144},"100605134","NCT07158567","Veterans' Intervention Blending NeuRomodulation and YogA for Chronic Low BackPaiN Treatment: VIBRANT","Veterans' Intervention Blending NeuRomodulation and YogA for Chronic Low Back PaiN Treatment: VIBRANT","VIBRANT","Inclusion Criteria:\n\n* 1 mo. stability in pain management strategies.\n* 22+ years of age.\n* Can read and speak English.\n* Able to participate in strengthening, stretching, range of motion exercise via yoga as determined by study physician.\n* Chronic Low Back Pain (CLBP): pain in the low back that persists for \\>6 months and is of moderate to severe intensity with a score of \\>5 on specific items on the BPI demonstrating disability of at least 20% on the Oswestry Disability Index (ODI).\n\nExclusion Criteria:\n\n* Contraindications to iTBS\u002FTMS (e.g. epilepsy, psychotic spectrum disorders \\[i.e. bipolar, schizophrenia\\], history of anoxic brain injury).\n* Moderate to severe heart disease.\n* Contraindications to MRI (e.g., claustrophobia, implanted ferromagnetic device such as pacemaker or cardiac defibrillator).\n* Pain believed to be associated with cardiac or ischemic conditions.\n* Epilepsy, active seizure disorder, personal history of a seizure or individuals with a family history of epilepsy or seizure in a first degree relative.\n* Current prescription of psychostimulants (e.g., amphetamines), anticholinergics, tricyclic antidepressants, and antipsychotics or other medications that may increase their risk of having seizures.\n* Intracranial lesion.\n* History of ischemic or hemorrhagic stroke.\n* History of moderate to severe TBI.\n* History of or current psychosis not due to an external cause (e.g., due to illicit drug use).\n* Other neurological conditions (e.g., neurodegenerative disorders).\n* Active suicidal ideation with Columbia Suicide Severity Rating Scale(CSSRS) 3 .\n* Are pregnant or nursing.\n* Within 12 weeks of a major surgery\u002Foperation.","22 Years",{"count":287,"type":20},213,[289],"PHASE3","The objectives of this VA Merit application are to demonstrate efficacy of combined intermittent theta burst (iTBS) and yoga (iTBS+yoga) intervention on improving pain, function, analgesic use, self-efficacy, quality of life and well-being among Veterans with chronic low back pain (CLBP). This Merit project will directly benefit Veterans and VA Services by demonstrating efficacy of a new, non-medication treatment for Veterans with CLBP in need of non-opioid treatment options. Neuromodulation including iTBS is now offered at over 50 VA hospitals and yoga is among the complementary and integrative health programs being rolled out as a part of VAs Whole Health implementation efforts. Thus, should iTBS+yoga ultimately prove to be efficacious, VA facilities will be well-poised to offer this treatment. A novel, activity-based, non-medication treatment for Veterans with CLBP is of great need given the high prevalence of CLBP.",[90,292],"Musculoskeletal Pain",[264,294,295,296,297,298,299],"transcranial magnetic stimulation","TMS","neuromodulation","yoga","complementary and integrative health","musculoskeletal pain","2026-06-03",{"date":217,"type":35},{"date":303,"type":20},"2026-07-01",{"date":305,"type":20},"2031-12-31",{"name":307,"class":308},"VA Office of Research and Development","FED",{"id":310,"slug":4,"hasResults":11,"nctId":311,"briefTitle":312,"officialTitle":312,"acronym":4,"eligibilityCriteria":313,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":120,"enrollmentInfo":314,"targetDuration":4,"studyType":52,"phases":316,"briefSummary":317,"conditions":318,"keywords":319,"overallStatus":216,"whyStopped":4,"lastUpdateSubmitDate":300,"lastUpdatePostDateStruct":326,"startDateStruct":327,"completionDateStruct":329,"leadSponsor":330,"locationsCount":75},"100511155","NCT05935761","Investigating Novel Interventions for Low Back Pain in US Military Veterans: A Randomized Controlled Adaptive Phase II Trial","Inclusion Criteria:\n\n* Veterans, 18-65 years of age with chronic low back pain.\n* Based on medical history and medical records, have low back pain (Thoracic Vertebrae 6 or below) present on most days for the preceding 6 months or longer, and fulfill all disease diagnostic criteria (please see disease diagnostic criteria below).\n* Have a weekly mean of 24-hour average pain score 4 at baseline.\n* Negative pregnancy test if female. Sexually active subjects are required to use a medically acceptable form of birth control if they are of childbearing potential and could become pregnant during the study. A medically acceptable form of birth control includes non-hormonal intrauterine devices, surgical sterilization, or double barrier methods (e.g. diaphragm with contraceptive jelly, condom with contraceptive foam, cervical caps with contraceptive jelly). Sexual abstinence with agreement to continue abstinence or to use a medically acceptable method of contraception (as listed above) should sexual activity occur is permissible.\n* No change in medications less than 4 weeks before baseline.\n* No anticipated need to alter psychotropic or pain medications for the 6-wk study duration (as determined by study physician's review of records and\u002For discussion with prescribing physician).\n* Ability to fully participate in the informed consent process.\n\nExclusion Criteria:\n\n* Unstable medical or neurological illness, including seizures, renal impairment or cerebral vascular accident (CVA).\n* Use of oral contraceptives or other hormonal supplements-this is out of caution, as it is unknown if the study medications would impact the efficacy of hormonal contraception.\n* Significant suicidal or homicidal ideation that necessitates intervention.\n* Daily use of long or short-acting narcotic medications (PRN use will be considered).\n* Current DSM-5 diagnosis of bipolar disorder, schizophrenia, or other psychotic disorder, or cognitive disorder due to a general medical condition.\n* Female participants who are pregnant or breast-feeding.\n* Known allergy to study medication.\n* History of moderate or severe TBI (mild TBI is permissible).\n* DSM-5 criteria met for alcohol and\u002For other substance abuse or dependence within past three months (excludes caffeine and nicotine).\n* Have received epidural steroids, facet block, nerve block or other invasive procedures aimed to reduce low back pain within the past 3 months prior to Visit 1.\n* Have ongoing or anticipated disability compensation or litigation issues, in the best judgment of the investigator.\n* Have a presence of any factors\u002Fconditions, medical or other, that in the judgment of the investigator may interfere with performance of study outcome measures, such as treatment-refractory history.\n* Have serious or unstable cardiovascular, hepatic, renal, metabolic, respiratory, or hematologic illness, symptomatic peripheral vascular disease, or other medical condition or psychiatric conditions that, in the opinion of investigator and study physician, would compromise participation or be likely to lead to hospitalization during the study.",{"count":315,"type":20},108,[155],"Chronic pain symptoms are very common among U.S. Military Veterans and have a profound negative impact on mental health symptoms and quality of life, in addition to increasing risk for suicidal ideation and suicidal behaviors. There are currently extremely few safe and effective pharmacological treatments for chronic pain disorders, and the clinical need to develop new therapeutics for pain has never been more urgent. Fueled by the worsening opioid crisis and further exacerbated by the COVID-19 pandemic, opioid and other drug overdose deaths have climbed to staggeringly high levels. The rapid development of medications for the management of chronic pain conditions that are safe, well-tolerated, efficacious and non-addicting is thus of paramount importance. The two neurosteroid candidates to be investigated in this trial are naturally occurring molecules enriched in human brain and potentially ideal candidates for safe and effective chronic pain treatment.",[90],[320,321,322,323,324,325],"neurosteroid","pregnenolone","DHEA","Veteran","Pain","Back",{"date":243,"type":35},{"date":328,"type":20},"2026-09-01",{"date":141,"type":20},{"name":307,"class":308},{"id":332,"slug":4,"hasResults":11,"nctId":333,"briefTitle":334,"officialTitle":335,"acronym":4,"eligibilityCriteria":336,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":337,"enrollmentInfo":338,"targetDuration":4,"studyType":52,"phases":340,"briefSummary":341,"conditions":342,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":343,"lastUpdatePostDateStruct":344,"startDateStruct":345,"completionDateStruct":347,"leadSponsor":349,"locationsCount":351},"100522272","NCT06080464","Clinician Satisfaction With the VERABAND™","A Study of Clinician Satisfaction and Likelihood of Clinical Adoption of the VERABAND™","Any treating clinician at a recruiting tertiary pain clinic will be eligible to participate.\n\nPatient participants must meet the following criteria:\n\nInclusion Criteria:\n\n* Ambulatory\n* Diagnosis of chronic low back pain (cLBP) according to the criteria of National Institute of Health (NIH) Task Force on Research Standards for cLBP\n* Answering 'Yes' to the question: Does your low back pain interfere with your mobility?\n* Starting any new non-surgical treatment or combination of treatments for cLBP as part of their normal ongoing care, including medications; physical therapy\u002Fexercise; integrated therapies (e.g., massage, acupuncture, yoga); cognitive- behavioral therapy; and\u002For interventional procedures (e.g., epidural steroid or facet joint injections)\n* Willingness to wear a VERABAND™ continuously until their next clinic visit and return used devices in the mail.\n\nExclusion Criteria:\n\n* Clinical findings suggesting the presence of ongoing systemic disease, including fever, weight loss, initiation of pain following major trauma, immunosuppression, intravenous drug use, recent bacterial infection, severe or persistent sensory or motor involvement of bowel, bladder, or lower extremity; or any condition that would greatly limit physical activity not due to pain.\n* Inability to speak and write English.\n* Visual or hearing difficulties that would preclude participation.\n* Severe psychiatric disorders that in the opinion of the investigative team would interfere with participation in the study. This includes any active suicidal ideations or history of suicide attempts. Exclusions will be based on self-reported medical history or chart review and in accordance with Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 criteria.\n* Individuals receiving disability or compensation or involved in litigation.\n* Scheduled surgery before follow-up.","85 Years",{"count":339,"type":20},360,[54],"The VERABAND™ is a newly-developed, disposable, wearable activity monitor. The researchers will assess clinician satisfaction with the usability and likelihood of clinical adoption of the newly-developed, disposable, wearable activity monitor, across multiple clinical sites in the chronic low back pain (cLBP) population.",[25],"2026-06-01",{"date":300,"type":35},{"date":346,"type":35},"2025-06-09",{"date":348,"type":20},"2027-06",{"name":350,"class":74},"University of Michigan",3,{"id":353,"slug":4,"hasResults":11,"nctId":354,"briefTitle":355,"officialTitle":355,"acronym":356,"eligibilityCriteria":357,"healthyVolunteers":11,"sex":16,"minAge":285,"maxAge":4,"enrollmentInfo":358,"targetDuration":4,"studyType":52,"phases":360,"briefSummary":361,"conditions":362,"keywords":364,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":369,"lastUpdatePostDateStruct":370,"startDateStruct":372,"completionDateStruct":374,"leadSponsor":376,"locationsCount":378},"100478314","NCT05508360","\"Lumbar Operatively Inserted PerQdisc Artificial Implant Following Nulcectomy\" (LOPAIN2)","LOPAIN2","Inclusion Criteria:\n\n* Patient is skeletally mature aged 22-70.\n* Patient has Degenerative Disc Disease (DDD) at one or more levels between L1 and S1 but the discogenic pain must be limited to a single level.\n* Patient has adequate disc height (6mm) at the level to be treated\n* Patient has exhausted a minimum of 6 months of conservative treatment for their back (e.g. physical therapy, medications, injections, life style changes, etc).\n* Patient has a preoperative Oswestry Disability questionnaire score ≥ 40 out of 100 points (40\u002F100)\n* Patient has a low back pain Visual Analog Scale (VAS) ≥ 40 mm (4 cm)\n* Patient has signed the approved Informed Consent Form.\n* All surgeries must be approved by the Medical Advisory Board (MAB)\n\nExclusion Criteria:\n\n* Patient has less than 6 mm of disc height.\n* Patient has had prior lumbar spine surgery (nucleoplasty at non-index level is considered acceptable).\n* Patient has had spinal fusion in the lumbar or thoracic intervertebral spaces. Cervical fusion is allowed as long as there are no neurologic deficits in the lower extremities.\n* Patient has spondyloarthropathy or other spondylolisthesis greater than 2 mm.\n* Patient has congenital moderate or severe spinal stenosis or epidural lipomatosis.\n* Patient has significant facet disease. Significant is defined as pain improvement of 80% or more following image-guided medial branch blocks of the target level according to SIS guidelines (diagnostic, contrast controlled).\n* Patient has any known active malignancy.\n* Patient has previously undergone or currently on immunosuppressive therapy. Steroids used to treat inflammation are allowed.\n* Patient has active or local systemic infection.\n* Patient has been diagnosed with hepatitis, rheumatoid arthritis, lupus erythematosus, or other autoimmune disease including AIDS, ARC and HIV.\n* Patient has diabetes mellitus (Type 1 or 2) requiring daily insulin management.\n* Patient has osteopenia of the spine (T-score of -1.0 or lower). A DEXA scan should be performed to rule out patients considered at risk for osteopenia.\n* Patient has morbid obesity defined as a body mass index (BMI) more than 40 or a weight of more than 45 kg (100 lbs.) over ideal body weight.\n* Patient has a known allergy to silicone or barium sulfate.\n* Patient has a significant disc herniation at the level to be treated. Significant is defined as a large, extruded herniation that creates a risk for expulsion.\n* Patient has a significant Schmorl's node in the level to be treated. Significant is defined as a large, rectangular or irregular shaped node that has an associated active inflammatory process (Modic I changes).\n* Patient has motion of less than 3 degrees on pre-operative lateral flexion\u002Fextension radiographs.\n* Patient belongs to a vulnerable population or has a condition such that his\u002Fher ability to provide informed consent, comply with follow-up requirements, or provide self-assessments is compromised (e.g. developmentally, disabled, prisoner, chronic alcohol\u002F substance abuser)\n\nIntraoperative Exclusion Criteria:\n\n* Protrusion of the 20A Imaging Balloon up to or beyond the outer margin of the vertebra during the imaging steps.\n* Patient has a violated endplate as determined by imaging balloons during fluoroscopy.\n* Patient has a disc space that is too narrow for implantation. MIPL Specific\n* Poor radiological visualization of Kambin's triangle.\n* Sustained irritation of the exiting nerve root during any aspect of the annular dilation technique (leg movement or if performing with electrical monitoring) in spite or repositioning instruments.",{"count":359,"type":20},72,[54],"This study will be a prospective, open-label, multi-center study including 72 patients that will collect additional safety and efficacy data for the Spinal Stabilization Technologies PerQdisc Nucleus Replacement System.",[363,25],"Degenerative Disc Disease",[363,365,90,366,367,368,30],"DDD","cLBP","Disc Herniation","Nucleus Replacement","2026-05-25",{"date":371,"type":35},"2026-05-27",{"date":373,"type":35},"2022-08-22",{"date":375,"type":20},"2030-08-22",{"name":377,"class":42},"Spinal Stabilization Technologies",10,{"id":380,"slug":4,"hasResults":11,"nctId":381,"briefTitle":382,"officialTitle":383,"acronym":4,"eligibilityCriteria":384,"healthyVolunteers":385,"sex":16,"minAge":17,"maxAge":386,"enrollmentInfo":387,"targetDuration":4,"studyType":52,"phases":389,"briefSummary":390,"conditions":391,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":393,"lastUpdatePostDateStruct":394,"startDateStruct":396,"completionDateStruct":398,"leadSponsor":399,"locationsCount":75},"100518027","NCT06025201","Detection of EEG-Based Biomarkers of Chronic Low Back Pain","Characterization of Longitudinal EEG Biomarkers in Chronic Low Back Pain","Inclusion Criteria:\n\n* Current diagnosis of Chronic Low Back Pain\n\nExclusion Criteria:\n\n* Current diagnosis of cancer\n* Severe psychiatric conditions\n* Pending personal litigation relating to an injury or receiving workers' compensation benefits\n* Being a non-English speaker.",true,"80 Years",{"count":388,"type":20},130,[54],"Chronic low back pain (CLBP) is a pervasive disorder affecting up to one-fifth of adults globally and is the single greatest cause of disability worldwide. Despite the high prevalence and detrimental impact of CLBP, its treatments and mechanisms remain largely unclear. Biomarkers that predict symptom progression in CLBP support precision-based treatments and ultimately aid in reducing suffering. Longitudinal brain-based resting-state neuroimaging of patients with CLBP has revealed neural networks that predict pain chronification and its symptom progression. Although early findings suggest that measurements of brain networks can lead to the development of prognostic biomarkers, the predictive ability of these models is strongest for short-term follow-up. Measurements of different neural systems may provide additional benefits with better predictive power.\n\nEmotional and cognitive dysfunction is common in CLBP, occurring at the behavioral and cerebral level, presenting a unique opportunity to detect prognostic brain-based biomarkers. Likewise, improvements in electroencephalogram (EEG) neuroimaging strategies have led to increased spatial resolution, enabling researchers to overcome the limitations of classically used neuroimaging modalities (e.g., magnetic resonance imaging \\[MRI\\] and functional MRI), such as high cost and limited accessibility. Using longitudinal EEG, this patient-oriented research project will provide a comprehensive neural picture of emotional, cognitive, and resting-state networks in patients with CLBP, which will aid in predicting symptom progression in CLBP. Through this award, the investigators will use modern EEG source analysis strategies to track biomarkers at baseline and 1- and 2-month follow-ups and their covariance with markers for pain and emotional and cognitive dysfunction. A 5-month follow up will also be used to only assess patient reported outcomes. In Aim 1, the investigators will identify and characterize differences in resting-state, emotional, and cognitive networks between patients with CLPB and age\u002Fsex-matched controls. In Aim 2, the investigators will identify within-subject changes across time and their relationship with clinical symptoms. In Aim 3, as an exploratory aim, the investigators will apply machine- and deep-learning strategies to detect a comprehensive signature of CLBP using EEG features from resting-state, emotional, and cognitive networks.",[25,392],"Healthy","2026-05-12",{"date":395,"type":35},"2026-05-15",{"date":397,"type":35},"2023-12-15",{"date":348,"type":20},{"name":400,"class":74},"Stanford University",{"id":402,"slug":4,"hasResults":11,"nctId":403,"briefTitle":404,"officialTitle":405,"acronym":4,"eligibilityCriteria":406,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":120,"enrollmentInfo":407,"targetDuration":4,"studyType":52,"phases":409,"briefSummary":410,"conditions":411,"keywords":412,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":416,"lastUpdatePostDateStruct":417,"startDateStruct":419,"completionDateStruct":421,"leadSponsor":422,"locationsCount":75},"100611513","NCT07241559","Effectiveness of Thoracolumbar Fascia Mobilization and Ultrasound-Guided 5% Dextrose Injection in Chronic Low Back Pain","Comparison of the Effectiveness of Thoracolumbar Fascia Mobilization and Ultrasound-Guided Thoracolumbar Interfascial 5% Dextrose Injection in Patients With Chronic Low Back Pain","Inclusion Criteria:\n\n1. Male or female patients aged 18 to 65 years\n2. Presence of low back pain lasting longer than 3 months\n3. No adequate response to medical treatment\n4. Voluntary participation in the study\n\nExclusion Criteria:\n\n1. Age below 18 or above 65 years\n2. Body mass index (BMI) greater than 30 kg\u002Fm²\n3. Pregnancy or breastfeeding\n4. Presence of coagulation disorders\n5. History of spinal surgery\n6. Presence of inflammatory or malignant diseases\n7. Local infection at the spine or injection site\n8. Presence of lumbar disc pathology causing radiculopathy\n9. Presence of spinal stenosis, spondylolysis, or spondylolisthesis\n10. Participation in physical therapy or any manual therapy within the past 6 months\n11. Receiving lumbar injections within the past 6 months\n12. History of allergy to injection materials\n13. Refusal to participate in the study",{"count":408,"type":20},75,[54],"The aim of this study is to investigate the effects of thoracolumbar fascia mobilization and ultrasound-guided thoracolumbar interfascial 5% dextrose injection on pain, range of motion, disability, quality of life, proprioception, and fascial thickness and echogenicity in patients with nonspecific chronic low back pain.\n\n-Primary Objective: The primary objective is to evaluate the effects of these interventions on pain, functional status and range of motion.\n\n-Secondary Objective: The secondary objective is to assess the long-term effects on quality of life, proprioception, fascial thickness, and echogenicity.",[90],[413,414,415],"Dextrose Injection","Mobilization","Thoracolumbar Fascia","2026-05-06",{"date":418,"type":35},"2026-05-07",{"date":420,"type":35},"2025-11-01",{"date":303,"type":20},{"name":423,"class":74},"Ankara City Hospital Bilkent",{"id":425,"slug":4,"hasResults":11,"nctId":426,"briefTitle":427,"officialTitle":427,"acronym":428,"eligibilityCriteria":429,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":430,"enrollmentInfo":431,"targetDuration":4,"studyType":52,"phases":433,"briefSummary":434,"conditions":435,"keywords":436,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":438,"lastUpdatePostDateStruct":439,"startDateStruct":441,"completionDateStruct":443,"leadSponsor":445,"locationsCount":351},"100579231","NCT06821607","Telerehabilitation for Patients With Chronic Low Back Pain (TeleBACK Clinical Trial)","TeleBACK","Inclusion Criteria:\n\n* Primary care visit in the past 90 days with an LBP-related ICD-10 diagnosis.\n* At least moderate levels of pain and disability requiring Oswestry score ≥24% and average pain rating ≥ 4\u002F10 points.\n* Meets NIH Task Force2 definition of chronic LBP based on two questions: 1) How long has LBP has been an ongoing problem? and 2) How often has LBP been an ongoing problem over the past 6 months? A response of greater than 3 months to question 1, and \"at least half the days in the past 6 months\" to question 2 is required to satisfy the NIH definition of chronic LBP.\n* Can speak and understand English or Spanish (Utah sites only).\n\nExclusion Criteria:\n\n* Recent history (last 6 months) of lumbar spine surgery.\n* Possible non-musculoskeletal cause for low back pain symptoms (e.g., pregnancy).\n* Evidence of serious pathology as a cause of LBP including neoplasm, inflammatory disease (e.g., ankylosing spondylitis), vertebral osteomyelitis, etc.\n* Neurological disorder resulting in severe movement disorder, or schizophrenia or other psychotic disorder.\n* Knowingly pregnant","64 Years",{"count":432,"type":20},1000,[54],"The investigators will conduct a prospective, randomized, clinical trial addressing key questions to understanding the effectiveness of telerehabilitation (physical therapy delivered via video-visits) and in-clinic physical therapy for patients with chronic low back pain (LBP). The investigators also seek to understand how patients engage with both care options and how these treatment options influence other LBP-related healthcare utilization.\n\nThe investigators will explore implementation outcomes using a mixed methods approach consisting of electronic surveys and semi-structured interviews with patients, physical therapists, practice managers, and outpatient services administration focusing on perceived quality and impact on barriers to care. The investigators will enroll 1000 patients with chronic LBP seeking outpatient care at the healthcare systems in Maryland (Johns Hopkins Medicine (JHM)) and Utah (University of Utah (UU) and Intermountain Healthcare (IHC)). Eligible patients will provide informed consent and be randomized to receive telerehabilitation or in-clinic physical therapy delivered by a trained physical therapist. Primary effectiveness outcome is the difference in change in LBP-related disability (Oswestry Disability Index) after 8 weeks of treatment.",[90],[264,265,437,267],"telehealth","2026-05-05",{"date":440,"type":35},"2026-05-08",{"date":442,"type":35},"2025-04-01",{"date":444,"type":20},"2030-05-01",{"name":277,"class":74},{"id":447,"slug":4,"hasResults":11,"nctId":448,"briefTitle":449,"officialTitle":450,"acronym":4,"eligibilityCriteria":451,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":452,"enrollmentInfo":453,"targetDuration":4,"studyType":52,"phases":455,"briefSummary":456,"conditions":457,"keywords":460,"overallStatus":216,"whyStopped":4,"lastUpdateSubmitDate":470,"lastUpdatePostDateStruct":471,"startDateStruct":472,"completionDateStruct":474,"leadSponsor":476,"locationsCount":4},"100639545","NCT07576062","Efficacy of Cognitive Functional Therapy in Individuals With Chronic Low Back Pain After Spinal Surgery","Efficacy of Cognitive Functional Therapy in Individuals With Chronic Low Back Pain After Spinal Surgery: A Randomized, Sham-Controlled Trial","Inclusion Criteria:\n\n* Age 18-75 years\n* Chronic low back pain ≥12 weeks\n* History of lumbar surgery ≥3 months\n* Pain intensity ≥3 (NPRS)\n* ODI ≥14%\n\nExclusion Criteria:\n\n* Serious spinal pathology\n* Neurological disorders\n* Radiculopathy\n* Pregnancy\n* Unstable cardiac conditions","75 Years",{"count":454,"type":20},90,[54],"Chronic low back pain after spinal surgery is a complex and disabling condition influenced by biopsychosocial factors. Cognitive Functional Therapy (CFT) is a promising intervention targeting these multidimensional aspects. This randomized, sham-controlled trial aims to compare the efficacy of CFT versus a sham intervention (detuned photobiomodulation) in participants with chronic low back pain after spinal surgery.",[90,458,459],"After Lumbar Spine Surgery","Failed Back Surgery Syndrome (FBSS)",[461,462,463,464,465,466,467,468,469],"Cognitive Functional Therapy","Spinal Surgery","Low-intensity light therapy","Placebo","Pain management","back pain","chronic pain","low back pain","Sham","2026-05-03",{"date":440,"type":35},{"date":473,"type":20},"2026-05",{"date":475,"type":20},"2027-11",{"name":477,"class":74},"Centro Universitário Augusto Motta",{"id":479,"slug":4,"hasResults":11,"nctId":480,"briefTitle":481,"officialTitle":482,"acronym":483,"eligibilityCriteria":484,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":485,"targetDuration":4,"studyType":52,"phases":487,"briefSummary":488,"conditions":489,"keywords":490,"overallStatus":216,"whyStopped":4,"lastUpdateSubmitDate":493,"lastUpdatePostDateStruct":494,"startDateStruct":495,"completionDateStruct":497,"leadSponsor":499,"locationsCount":75},"100554375","NCT06498271","Personalized and Automated Digital Coaching in People With Non-specific Chronic Low Back Pain","Personalized and Automated Digital Coaching in People With Non-specific Chronic Low Back Pain: a Randomized Controlled Trial Nested in the \"ComPaRe\" E-cohort","BACK-4P","Inclusion Criteria:\n\n* Adults aged 18 or over\n* Having non-specific chronic LBP\n* Participating in the \"ComPaRe\" e-cohort\n* Having provided consent for their data to be used to assess trial eligibility\n\n  * And to be randomized if eligible\n  * And to, allow their data to be used to evaluate intervention effectiveness without being notified that they are in the control group, if randomized to usual the control group\n* Having a valid email address\n* Able to read and write French Having a smartphone functioning with Android acquired after 2020\n\nExclusion Criteria:\n\n* No exclusion criteria",{"count":486,"type":20},330,[54],"The investigators hypothesize that a personalized and automated digital coaching could reduce activity limitations in people with chronic low back pain as compared to usual care",[90],[491,492],"Chronic low back pain","Digital coaching","2026-04-30",{"date":416,"type":35},{"date":496,"type":20},"2026-09",{"date":498,"type":20},"2028-03",{"name":500,"class":74},"Assistance Publique - Hôpitaux de Paris",{"id":502,"slug":4,"hasResults":11,"nctId":503,"briefTitle":504,"officialTitle":505,"acronym":506,"eligibilityCriteria":507,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":120,"enrollmentInfo":508,"targetDuration":4,"studyType":52,"phases":510,"briefSummary":511,"conditions":512,"keywords":513,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":520,"lastUpdatePostDateStruct":521,"startDateStruct":523,"completionDateStruct":525,"leadSponsor":526,"locationsCount":75},"100506886","NCT05880212","Implementation of the Specific Treatment Of Problems of the Spine Approach in Bangladesh","Implementation of the Specific Treatment Of Problems of the Spine (STOPS) Approach in Bangladesh: A Prospective Sequential Comparison","STOPS-Bangla","Inclusion Criteria:\n\nPhysiotherapists:\n\nQualified physiotherapists and physiotherapy assistants in Bangladesh who are involved in low back pain management and working in either or both trial settings will provide the treatment in phases 1 and 3. To be eligible, physiotherapists and physiotherapy assistants must be willing to participate in all phases of the trial (Phases I, II, and III). They must have completed the organised STOPS training course led by the original Australian developers (Jon Ford and Andrew Hahne), where the assessment and treatment protocols will be taught in Phase II.\n\nPatients:\n\n1. A primary complaint of either:\n\n   1. low back pain, defined as pain between the inferior costal margin and the inferior gluteal fold with or without referral into the leg(s)\n\n      or\n   2. referred leg pain, defined as predominately unilateral posterior leg pain extending below the knee, or anterior thigh pain, with or without back pain\n2. Duration of the current episode of primary complaint lasting for greater than 3 months (chronic stage of the injury)\n3. Aged between 18 and 65 (inclusive)\n4. Fluency in English or Bengali sufficient to complete questionnaires and to enable understanding of the intervention\n5. Agreeing to refrain from other interventions wherever possible for the 10-week treatment period of the trial, aside from consultations with medical practitioners, medication, and any exercises already being undertaken\n\nExclusion Criteria:\n\nPhysiotherapist:\n\nNot willing to participate in the study for all 3 phases.\n\nPatient:\n\n1. Red flag pathologies such as active cancer under current treatment, risk of spinal fracture, signs of potential infection, and major systemic inflammatory disease.\n2. Signs of cauda equina syndrome based on bladder or bowel disturbance and\u002For imaging\n3. Current pregnancy, or childbirth within the last 6 months, as this could impair the ability to undertake exercises, and could also cause back and leg symptoms that are not related to the subgroups under investigation\n4. Spinal injections within the last 6 weeks, as we wish to study treatment effects independent of the effects of injections\n5. Any history of lumbar spine surgery, as there is already considerable research evaluating the efficacy of post-surgical rehabilitation programs\n6. A pain intensity score of less than 2\u002F10 on the numerical pain rating scale due to low severity.\n7. Minimal activity limitation, evidenced by a baseline ability to perform ALL of (walk, sit, and stand for one hour or more and no sleep disturbance at night), as we wish to exclude people with low severity.\n8. Inability to walk safely, such as severe foot drop causing regular tripping, as the interventions in the trial include walking for most participants.\n9. Planned absence of more than one week during the treatment period (such as holidays).",{"count":509,"type":20},154,[54],"The goal of this implementation trial is to evaluate the clinical outcomes associated with usual physiotherapy care compared to individualized physiotherapy in accordance with the Specific Treatment of Problems of the Spine (STOPS) approach in patients with chronic low back pain (CLBP). The main questions it aims to answer are:\n\n* Is the STOPS approach more effective than usual care physiotherapy among patients with CLBP?\n* Is STOPS physiotherapy cost-effective compared to usual physiotherapy care for patients with CLBP.\n* Does STOPS training improve the quality of care among Bangladeshi physiotherapists?",[25],[491,514,515,516,517,518,519],"Physiotherapy","Usual care","STOPS","Implementation trial","Bangladesh","Physiotherapist","2026-04-27",{"date":522,"type":35},"2026-05-04",{"date":524,"type":35},"2023-08-01",{"date":67,"type":20},{"name":527,"class":74},"Mohammad Ali",{"id":529,"slug":4,"hasResults":11,"nctId":530,"briefTitle":531,"officialTitle":532,"acronym":533,"eligibilityCriteria":534,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":535,"targetDuration":4,"studyType":52,"phases":537,"briefSummary":538,"conditions":539,"keywords":540,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":520,"lastUpdatePostDateStruct":548,"startDateStruct":549,"completionDateStruct":551,"leadSponsor":553,"locationsCount":554},"100373419","NCT04142177","Sequential and Comparative Evaluation of Pain Treatment Effectiveness Response","CSP #2009 - Sequential and Comparative Evaluation of Pain Treatment Effectiveness Response: The SCEPTER Trial","SCEPTER","Inclusion Criteria:\n\nTo be eligible to participate in this study, an individual must meet all the following criteria:\n\n1. Low back pain\n\n   1. present for at least 6 months,\n   2. present most days or everyday,\n   3. interferes the most with activities considering all of the places where the patient experiences pain;\n2. Pain, Enjoyment, General Activity (PEG) score of 4 or greater;\n3. Veteran age 18 years or older, either sex, any racial or ethnic background;\n4. Able to comprehend and willing to sign the study informed consent form;\n5. Able and willing to attend in-person treatment sessions;\n6. Anticipate continuing care at the enrolling VA for the period of the study;\n7. Stable access to the internet at home, work, or other location (e.g. mobile phone), and an email address.\n\nExclusion Criteria:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n1. Currently enrolled in any other interventional study unless exempted by CSP;\n2. Acute or chronic illness that would prevent the Veteran from receiving study treatments offered (e.g., uncontrolled hypertension, recent myocardial infarction within the last 6 months, unstable angina, acute congestive heart failure);\n3. Neurological impairment related to disease of the spine or other causes preventing participation in any of the treatment modalities under study;\n4. Current or recent (last 3 months) treatment involving Cognitive Behavioral Therapy, Spinal manipulation therapy, or Yoga;\n5. Current severe alcohol or substance abuse use disorder;\n6. Severe psychiatric illness (e.g. current psychosis, current suicidal ideation, or psychiatric illness requiring hospitalization within the last 6 months);\n7. Back surgery within the last 6 months, or undergoing evaluation for back surgery or planned back surgery;\n8. Cognitive or severe hearing or visual impairment preventing participation in treatment options or outcome measure assessments;\n9. Pregnancy",{"count":536,"type":20},2529,[54],"VETERANS ONLY. Chronic low back pain (cLBP) is common. Most Americans will have at least one episode of low back pain in their lifetimes. Approximately 50% of all US Veterans have chronic pain, and CLBP is the most common type of pain in this population. This study will use a sequential randomized, pragmatic, 2-step comparative effectiveness study design. The main goal is to identify the best approach for treating cLBP using commonly recommended non-surgical and non-pharmacological options. The first step compares continued care and active monitoring (CCAM) to internet-based pain self-management (Pain EASE) and an enhanced physical therapy intervention that combines Pain EASE with tailored exercise and physical activity. Patients who do not have a significant decrease in pain interference (a functional outcome) in Step 1 and those desiring additional treatment will be randomized in Step 2 to yoga, spinal manipulation therapy (SMT), or therapist-delivered cognitive behavioral therapy (CBT). Participants proceeding to randomization in Step 2 will be allowed to exclude up to one of the three Step 2 treatments based on their preferences. The investigators' primary hypothesis for the first treatment step is that an enhanced physical therapy intervention that combines pain self-management education with a tailored exercise program will reduce pain interference greater than internet-based pain self-management alone or CCAM in Veterans with cLBP. The primary outcome is change in pain interference at 3 months, measured using the Brief Pain Inventory (BPI) pain interference subscale. Study participants will be followed for one year after initiation of their final study treatments to assess the durability of treatment effects. The study plans to randomize 2529 patients across 20 centers.",[90],[264,541,542,543,544,265,545,297,546,547],"severe low back pain","pain","non-pharmacological treatment","self-management","exercise","cognitive behavioral therapy","spinal manipulation therapy",{"date":522,"type":35},{"date":550,"type":35},"2022-06-13",{"date":552,"type":20},"2027-06-30",{"name":307,"class":308},19,{"id":556,"slug":4,"hasResults":11,"nctId":557,"briefTitle":558,"officialTitle":559,"acronym":4,"eligibilityCriteria":560,"healthyVolunteers":11,"sex":16,"minAge":561,"maxAge":120,"enrollmentInfo":562,"targetDuration":4,"studyType":52,"phases":563,"briefSummary":564,"conditions":565,"keywords":566,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":570,"lastUpdatePostDateStruct":571,"startDateStruct":573,"completionDateStruct":575,"leadSponsor":577,"locationsCount":75},"100628551","NCT07463105","Virtual Reality-Based Rehabilitation Versus Conventional Therapy in Patients With Chronic Low Back Pain","Effects of Virtual Reality-Based Rehabilitation Compared With Conventional Physiotherapy on Motor and Psychosocial Function in Patients With Chronic Low Back Pain: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Diagnosis of chronic low back pain lasting at least 3 months\n* Average pain intensity ≥4\u002F10 during the previous week on the Numeric Rating Scale (NRS)\n* Age between 40 and 65 years\n* Ability to walk independently without assistive devices\n* Functional disability related to low back pain defined as Oswestry Disability Index (ODI) ≥15%\n* No contraindications to participation in a physiotherapy program or virtual reality training\n* Ability to understand study procedures and follow instructions\n* Written informed consent to participate in the study\n\nExclusion Criteria:\n\n* Acute low back pain or pain lasting less than 3 months\n* Neurological, orthopedic, rheumatological, oncological diseases or active inflammatory conditions that may affect study outcomes\n* Cognitive impairment limiting the ability to understand instructions or participate in rehabilitation\n* Contraindications to virtual reality training such as severe dizziness, nausea, epilepsy, or severe visual or auditory impairment\n* Contraindications to body composition analysis (e.g., implanted cardiac pacemaker or other electronic implants)\n* Unstable medical condition or uncontrolled cardiovascular or respiratory disorders preventing participation in rehabilitation\n* Participation in other rehabilitation programs during the study period\n* Failure to complete the four-week rehabilitation program\n* Lack of written informed consent","40 Years",{"count":200,"type":20},[54],"This study aims to evaluate the effectiveness of rehabilitation using virtual reality compared with conventional physiotherapy in patients with chronic low back pain. The study will be conducted as a prospective, randomized controlled trial including 80 patients aged 40-65 years diagnosed with chronic low back pain lasting at least three months. Participants will be randomly assigned to two groups: an experimental group receiving conventional rehabilitation supplemented with non-immersive virtual reality training using the Tecnobody Homing Studio system, and a control group receiving conventional rehabilitation alone.\n\nBoth groups will participate in a four-week rehabilitation program. The virtual reality training will replace a portion of conventional exercises and will focus on improving movement quality, postural control, coordination, and functional mobility through interactive tasks with visual and auditory biofeedback. The system utilizes a 3D camera enabling markerless motion analysis and real-time visual feedback to support movement correction and identification of functional deficits.\n\nOutcome measures will include assessments of balance, posture, joint mobility, lower limb strength and endurance, pain intensity, pressure pain threshold, kinesiophobia, perceived stress, anxiety and depression, functional disability, quality of life, and motivation for physical activity. Measurements will be conducted at baseline, immediately after completion of the four-week rehabilitation program, and at an eight-week follow-up.\n\nThe results of this study are expected to provide clinical evidence regarding the effectiveness of virtual reality-assisted rehabilitation in patients with chronic low back pain and may contribute to the development of evidence-based rehabilitation strategies incorporating digital technologies.",[90],[90,567,568,569],"Virtual Reality Rehabilitation","Kinesiophobia","Postural Control","2026-04-18",{"date":572,"type":35},"2026-04-22",{"date":574,"type":20},"2026-04-01",{"date":576,"type":20},"2027-05-31",{"name":578,"class":74},"University of Rzeszow",{"id":580,"slug":4,"hasResults":11,"nctId":581,"briefTitle":582,"officialTitle":583,"acronym":584,"eligibilityCriteria":585,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":586,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":588,"conditions":589,"keywords":593,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":599,"lastUpdatePostDateStruct":600,"startDateStruct":602,"completionDateStruct":604,"leadSponsor":606,"locationsCount":75},"100555914","NCT06518278","Assessing Central Aspects of Pain","Assessing Central Nervous System Contributions to Accelerate Musculoskeletal Pain Diagnosis and Treatment","AsCent","Inclusion Criteria:\n\n* Adults aged 18 years or over.\n* One for more of the following self-reported diagnoses: fibromyalgia, inflammatory MSK condition (e.g., rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis), low back pain, osteoarthritis.\n* MSK diagnosis and pain onset more than 3 months prior to baseline\n* Self-reported pain levels ≥ 3 on a 0 to 10 numerical rating scale where 0 = 'no pain' and 10 = 'worst pain imaginable' on most days in the 3 months before baseline.\n* Ability to give informed consent.\n\nExclusion Criteria:\n\n* Terminal\u002Funcontrolled medical or mental health condition that would prevent participants from completing assessments or pose a significant risk to participants or staff.\n* Insufficient understanding of spoken or written English to comply with the requirements of the study protocol.\n* Inability to adhere to the study protocol.",{"count":587,"type":20},250,"BACKGROUND: Chronic pain continues for more than 12 weeks despite medication or treatment. Chronic pain is the main symptom of muscle and joint problems, rarely explained by damage to the muscle and joints alone. Activity in the central nervous system (CNS; nerves, spinal cord, and brain) pathways governs our ability to describe pain intensity and our emotional response to pain. Musculoskeletal conditions (e.g., inflammatory arthritis, osteoarthritis, low back pain, fibromyalgia) share altered CNS pathways, acknowledged by recent classifications of 'primary' and 'nociplastic' pain. Clinically useful tools to diagnose and measure activity and reveal abnormalities in these CNS pathways are needed to improve clinical decisions and accelerate new treatment development. Laboratory pain sensitivity testing and brain imaging confirm the CNS as a primary contributor to pain. These assessments are less acceptable or unfeasible for clinical practice. Simpler clinical pain sensitivity assessments are being developed. The investigators simple Central Aspects of Pain (CAP) questionnaire detects some people with pain sensitivity and knee, rheumatoid arthritis or low back pain. Combining the CAP questionnaire reflecting emotional processing and simpler pain sensitivity assessment, combining two different dimensions should be better than either approach alone.\n\nPURPOSE: To optimise diagnosis and measurement of CNS as the primary contribution to chronic musculoskeletal pain by using the CAP questionnaire and simpler pain sensitivity assessments to ensure timely, effective diagnosis and treatment.\n\nOBJECTIVES: 1. Assess the ease, ability and performance of the combined CAP questionnaire and simpler pain sensitivity assessments to identify CNS as the primary contributor to chronic pain across musculoskeletal conditions.\n\n2\\. Use the CAP questionnaire alone or with substitute measures of activity in CNS pathways, demographic, and clinical variables to indicate pain levels at six and twelve weeks.\n\n3\\. Understand the relationship between CAP and simpler pain sensitivity assessment with laboratory pain sensitivity assessments as a tool to inform the current CNS activity contributing to pain.\n\n4\\. Evaluate associations between the CAP questionnaire and simpler pain sensitivity assessments with patient outcomes.",[590,591,90,592],"Osteoarthritis","Fibromyalgia","Inflammatory Arthritis",[594,595,596,597,598],"Quantitative Sensory Testing","Temporal Summation","Pressure Pain detection Threshold","Conditioned Pain Modulation","Offset Analgesia","2026-04-02",{"date":601,"type":35},"2026-04-08",{"date":603,"type":35},"2024-10-23",{"date":605,"type":20},"2026-10",{"name":607,"class":74},"University of Nottingham",{"id":609,"slug":4,"hasResults":11,"nctId":610,"briefTitle":611,"officialTitle":612,"acronym":4,"eligibilityCriteria":613,"healthyVolunteers":11,"sex":16,"minAge":83,"maxAge":120,"enrollmentInfo":614,"targetDuration":4,"studyType":52,"phases":616,"briefSummary":617,"conditions":618,"keywords":619,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":574,"lastUpdatePostDateStruct":624,"startDateStruct":626,"completionDateStruct":627,"leadSponsor":628,"locationsCount":75},"100628599","NCT07463729","Evaluation of Stabilization Training With Biofeedback in Lumbosacral Spine Pain Syndrome","Evaluation of the Effectiveness of Stabilization Training With Biofeedback in Patients With Lumbosacral Spine Pain Syndrome","Inclusion Criteria:\n\n* Diagnosed chronic lumbosacral spine pain syndrome (score \\>4 on the Keele STarT Back Screening Tool)\n* Lumbosacral pain intensity \\>3 on the Visual Analog Scale (VAS) persisting for at least the past 3 months\n* Age between 30 and 65 years\n* No concurrent participation in another rehabilitation program\n* Provision of written informed consent to participate in the study\n\nExclusion Criteria:\n\n* Acute phase of lumbosacral spine pain syndrome\n* Presence of neurological symptoms such as paresthesia, dysesthesia, impaired superficial sensation, impaired pain sensation, muscle strength below grade 3 on the Lovett scale in the lower limbs, sphincter dysfunction, or cauda equina syndrome\n* Recent fractures of the spine or pelvis (less than 6 months since injury)\n* Segmental instability confirmed by functional X-ray or magnetic resonance imaging (MRI)\n* Spondylolisthesis greater than Grade I according to the Meyerding classification\n* Coexisting neurological (e.g., Parkinson's disease, neuropathies), autoimmune (e.g., ankylosing spondylitis), orthopedic (lower limb disorders), or oncological diseases\n* Pregnancy\n* Active use of analgesic or anti-inflammatory pharmacotherapy (e.g., steroids, NSAIDs)\n* Concurrent participation in other rehabilitation programs or failure to complete the 8-week therapy program\n* Completion of any structured rehabilitation program within the past 3 months\n* Lack of informed consent to participate in the study",{"count":615,"type":20},110,[54],"The aim of the study is to evaluate the effects of biofeedback-assisted stabilization training and conventional therapy on pain perception, balance, spinal mobility, functional performance, physical activity, stress level, and quality of life in patients with lumbosacral spine pain syndrome treated conservatively. The main research questions the study seeks to answer are as follows: Whether and to what extent the implemented therapeutic program improves balance, spinal mobility, functional performance, physical activity, quality of life, and reduces pain perception and stress levels in patients with lumbosacral spine pain syndrome? Are there differences in therapeutic outcomes depending on the treatment method applied? Are the therapeutic effects maintained three months after completion of the intervention? Researchers will compare two groups: a control group and an experimental group. In the control group, stabilization training will be performed without the use of biofeedback. Participants will undergo clinical and functional assessments (Visual Analogue Scale, Oswestry Disability Index, force platform measurements, etc.). Depending on the group to which participants are randomly assigned, participants will participate in manual therapy, stabilization training, and selected physical therapy modalities. Participants will be continuously supervised by a physician and physiotherapists throughout the 8-week intervention period. Three months after completion of the intervention, participants will undergo a follow-up assessment.",[30,90],[491,620,621,622,623],"RUSI","UltrasoundBiofeedback","StabilizationExercises","LumbarStabilization",{"date":625,"type":35},"2026-04-07",{"date":574,"type":35},{"date":552,"type":20},{"name":578,"class":74},{"id":630,"slug":4,"hasResults":11,"nctId":631,"briefTitle":632,"officialTitle":633,"acronym":4,"eligibilityCriteria":634,"healthyVolunteers":11,"sex":16,"minAge":635,"maxAge":337,"enrollmentInfo":636,"targetDuration":4,"studyType":52,"phases":638,"briefSummary":639,"conditions":640,"keywords":641,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":646,"lastUpdatePostDateStruct":647,"startDateStruct":649,"completionDateStruct":651,"leadSponsor":653,"locationsCount":75},"100624923","NCT07415941","MBM and taVNS for Low Back Pain and Depressive Symptoms","Home-based Mindfulness-based Meditation and Transcutaneous Auricular Vagus Nerve Stimulation for Older Adults With Low Back Pain and Depressive Symptoms","Inclusion Criteria:\n\n1. aged 50 to 85 years old\n2. intact cognition (examined by the Mini-Mental State Exam, ≥ 24)\n3. experiencing moderate low back pain daily or almost every day at least the previous three months (≥3 out of 10 on numeric rating scale \\[NRS\\])\n4. experiencing elevated depressive symptoms with the patient health questionnaire (PHQ-9) total score ranging between 5 to 19\n5. able to speak and read English\n6. not intent to change medication regimens for pain throughout the trial.\n\nExclusion Criteria:\n\n1. serious underlying illness (e.g., malignant neoplasms),\n2. other psychosis,\n3. elevated suicide risk as indicated by the Columbia-Suicide Severity Rating Scale (C-SSRS) score \\> 2,\n4. function limitation precluded the meditation practice,\n5. participated meditation program before,\n6. any other conditions\u002Fcontraindications that prohibit the application of taVNS including but not limited to any current or past history of cardiovascular disorders, recent ear trauma, and metal implants above the level of the neck,\n7. no access to the internet.","50 Years",{"count":637,"type":20},66,[54],"This two-arm randomized controlled trial aims to test the preliminary effect of home-based mindfulness-based meditation and transcutaneous auricular vagus nerve stimulation on managing pain and depressive symptoms among community-dwelling older adults with chronic low back pain and depressive symptoms; and the effect of home-based mindfulness-based meditation and transcutaneous auricular vagus nerve stimulation on the host Brain-Gut Axis.",[90],[642,643,644,645],"depressive symptoms","older adults","mindfulness","taVNS","2026-03-23",{"date":648,"type":35},"2026-03-25",{"date":650,"type":35},"2026-01-30",{"date":652,"type":20},"2027-12-31",{"name":654,"class":74},"Florida State University",""]